Eloralintide
- Generic Name
- Eloralintide
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT06916091
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
- Conditions
- OverweightObesity
- Interventions
- Drug: Eloralintide and Tirzepatide
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 188
- Registration Number
- NCT06916065
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 350
- Registration Number
- NCT06603571
- Locations
- 🇺🇸
NorCal Medical Research, Inc, Greenbrae, California, United States
🇺🇸Velocity Clinical Research, Huntington Park, Huntington Park, California, United States
🇺🇸Peninsula Research Associates, Rolling Hills Estates, California, United States
A Study of LY3841136 in Overweight and Obese Participants
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 96
- Registration Number
- NCT06345066
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT06297616
- Locations
- 🇯🇵
P-One Clinic, Hachioji, Tokyo, Japan
🇯🇵Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵Hakata Clinic, Fukuoka, Japan
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
- Conditions
- ObesityOverweight and Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT06230523
- Locations
- 🇺🇸
Headlands Research - Detroit, Southfield, Michigan, United States
🇺🇸Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy, Michigan, United States
🇺🇸StudyMetrix Research, Saint Peters, Missouri, United States
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1040
- Registration Number
- NCT06143956
- Locations
- 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸HOPE Research Institute, Phoenix, Arizona, United States
🇺🇸Headlands Research - Scottsdale, Scottsdale, Arizona, United States
A Study of LY3841136 in Healthy and Overweight Participants
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 148
- Registration Number
- NCT05295940
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.